37557-40-7

Usage

Uses

Used in Organic Synthesis:
N-O-TOLYL-GUANIDINE is used as a reagent in organic synthesis for its ability to participate in a range of chemical reactions, facilitating the creation of diverse organic compounds.
Used in Pharmaceutical Industry:
N-O-TOLYL-GUANIDINE is used as a precursor in the development of pharmaceutical products, leveraging its chemical properties to contribute to the synthesis of new medications.
Used in Agricultural Products:
In the agricultural sector, N-O-TOLYL-GUANIDINE is utilized as a precursor to help formulate various agricultural products, potentially enhancing crop protection and yield.
Used in Therapeutic Applications:
N-O-TOLYL-GUANIDINE is studied for its potential therapeutic applications, particularly in the treatment of diabetes and neurodegenerative diseases, indicating its possible role in future medicinal advancements.
While the provided materials do not specify different industries for each application, the general uses listed above cover the broad areas where N-O-TOLYL-GUANIDINE is known to be applied. Further research and development could reveal more specific applications within various industries.

Upstream product

• 420-04-2 CYANAMID 
• 636-21-5 o-toluidine hydrochloride 
• 88-72-2 1-methyl-2-nitrobenzene 
• 95-53-4 o-toluidine 

Downstream Products

• 1610886-17-3 3,4-dimethyl-5-(2-(o-tolylamino)pyrimidin-4-yl)thiazol-2(3H)-one 
• 1186620-29-0 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzenesulfonic acid N'-(2,4,6-trichlorobenzoyl)hydrazide 
• 1186620-62-1 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzenesulfonyl chloride 

Relevant academic research and scientific papers

Discovery of CDK5 Inhibitors through Structure-Guided Approach

Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based in silico screenin

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation

Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumourigenesis and development. Targeting Mnks may provide a novel anticancer therapeutic strategy. However, the lack of selective Mnk inhibitors has so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino) pyrimidin-4-yl)thiazole-2(3H)-one derivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors. Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukaemia cells. Highly active Mnk2 inhibitors: Mnk-related cancer biology is an area of intensive research, but its inhibitor discovery has lagged behind due to a lack of understanding of the protein structure. Herein we report the discovery of Mnk2 inhibitors (e.g. 8 e). These potent and selective inhibitors are extremely valuable for target validation and drug discovery.

Reaction of quinones and guanidine derivatives: Simple access to bis-2-aminobenzimidazole moiety of benzosceptrin and other benzazole motifs

A new strategy for the synthesis of 2-aminobenzimidazol-6-ols via a reaction of quinones with guanidine derivatives is reported. Sequential application of this methodology provided a simple access to the first benzosceptrin analogue bearing a bis-2-aminoimidazole moiety. A concomitant addition of two guanidines to the naphtho[1′,2′:4,5]imidazo[1,2-a] pyrimidine-5,6-dione, which includes the redox neutral debenzylation and guanidine-assisted cleavage of the 2-aminopyrimidine part resulted in the synthesis of the free challenging contiguous bis-2-aminoimidazole moiety of benzosceprins in one step.

Curable composition

The present invention has its object to provide a curable composition which comprises a reactive silyl group-containing organic polymer, does not contain, as a silanol condensation catalyst, any organotin type curing catalyst currently of concern because

CURABLE COMPOSITION

The present invention has its object to provide a curable composition which comprises a guanidine compound as a non-organotin type catalyst, is less discolored, has good surface curability, depth curability, strength rise and adhesiveness, and can retain the curability even after storage; the above object can be achieved by a curable composition which comprises: (A) an organic polymer containing a silyl group capable of crosslinking under siloxane bond formation, the silyl group being a group represented by the general formula (1): -SiX 3 (1) (wherein X represents a hydroxyl group or a hydrolyzable group and the three X groups may be mutually the same or different), (B) a guanidine compound (B-1) as a silanol condensation catalyst, and (C) a plasticizer, wherein the content of the component (B-1) is not lower than 0.1 part by weight but lower than 8 parts by weight per 100 parts by weight of the component (A), and a non-phthalate ester plasticizer accounts for 80 to 100% by weight of the (C) component plasticizer.

Pharmaceutical guanidine preparations and methods of using same

Pharmaceutical preparations and methods of using the same to treat a host having a condition requiring vasoconstrictive therapy. The preparations comprise a pharmaceutically acceptable carrier and a guanidine compound, or non-toxic acid addition salt ther